Comparison of 18F PSMA-1007 PETCT and Conventional Imaging in the Detection of Metastatic Clear Cell Renal Cell Carcinoma

Led by Western University · Updated on 2024-06-25

Participants Needed

Research Sites

39 weeks

Total Duration

AI-Summary

What this Trial Is About

Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.

CONDITIONS

Brief Title

[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

Inclusion Criteria:

Men and women with histologically-proven, metastatic renal cell carcinoma (RCC)(TNM stage Tany, Nany, M1)
Must have baseline conventional imaging of the chest, abdomen, and pelvis with contrast-enhanced CT or MRI within 5 weeks of enrolment. Contrast is required unless the participant cannot for medical reasons (ie renal failure).

Exception: Unenhanced CT of the chest is acceptable Exception: Unenhanced MRI of abdomen and pelvis is acceptable in cases of renal failure

Exclusion Criteria:

Pregnant or breastfeeding
Age less than 18
Histology does not have any clear cell component
Unable to lie flat for 30 minutes for the scan
History of prior malignancy (except non-melanoma skin cancer)
Unable to provide informed consent
Inadequate liver function
Systemic or radiation-based cancer treatment is needed urgently and anticipated to begin before PSMA scan can take place
Previously exposed to systemic or radiation cancer therapy (except radiation for skin cancer)

Research Team

Kaydee Connors

Nicole Phillips

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here